Related Experiment Video
Updated: Jul 13, 2026
07:35
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Quantitative science methods for biomarker validation in chemoprevention trials
1Bar Ilan University and Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer, Israel. lsf@actcom.co.il
Cancer Biomarkers : Section a of Disease Markers
|July 6, 2007
Summary
Using surrogate outcomes in cancer research can reduce study size and cost. However, validating these biomarkers is crucial for reliable intervention effect evidence, especially in cancer chemoprevention.
Area of Science:
- Oncology
- Biostatistics
- Clinical Trial Design
Background:
- Cancer intervention studies using incident cancer as an outcome are often large, lengthy, and costly due to the low probability of malignancies.
- Surrogate outcomes, such as biomarkers of pre-clinical carcinogenesis, offer a potential solution by enabling smaller, shorter, and less expensive studies.
- Validation of surrogate outcomes is essential to ensure they provide high-quality evidence on intervention effects comparable to traditional cancer outcomes.
Purpose of the Study:
- To review methods proposed over the last 15 years for validating surrogate outcomes in cancer research.
- To evaluate the practicality and limitations of different validation approaches, particularly for cancer chemoprevention studies.
Main Methods:
- Review of validation methods for surrogate outcomes, focusing on two main approaches: Prentice criterion-based (single study) and meta-analysis-based (multiple studies).
- Discussion of the reasons for the decline in popularity of the Prentice criterion approach.
- Assessment of the resource demands and practicality of meta-analysis-based validation for cancer chemoprevention.
Main Results:
- The Prentice criterion approach for surrogate outcome validation has become less favored.
- Meta-analysis-based validation is more popular but resource-intensive, potentially limiting its application in cancer chemoprevention.
- The practical utility of surrogate outcomes may be restricted to Phase II studies for selecting interventions for Phase III testing.
Conclusions:
- While surrogate outcomes offer advantages in efficiency for cancer research, their validation remains a critical challenge.
- Meta-analysis-based validation, though robust, presents significant resource challenges for widespread use in cancer chemoprevention.
- A more limited role for surrogate outcomes, primarily in early-phase trials, may be necessary given current validation constraints.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Data Validation
Method validation is a crucial process in analytical chemistry designed to confirm that a given method consistently produces reliable and high-quality results. This process is essential when a method is applied to different sample matrices or when procedural modifications are made, ensuring that the results meet acceptable standards across various applications.
Key parameters for method validation include:
Key parameters for method validation include:
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...